Geron Plans to Announce Second Quarter 2026 Financial Results on August 5, 2026
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Geron (Nasdaq: GERN) announced it will release its second quarter 2026 financial results and business highlights before the market opens on Wednesday, August 5, 2026. The company will host a conference call and webcast at 8:00 a.m. Eastern Time, accessible via the Investors and Media section of its website.
Details
News Market Reaction – GERN
On Jul 22, the day this news came out, GERN closed 2.08% below the previous close.
Data tracked by StockTitan Argus for the Jul 22 session.
Key Figures
- Reporting period
- Q2 2026
- Financial results and business highlights
- Release date
- August 5, 2026
- Before the market opens
- Conference call time
- 8:00 a.m. Eastern Time
- Conference call and webcast
Previous Earnings date Reports
-
Scheduled first-quarter results and business highlights before the May 6 market open
-
Scheduled fourth-quarter and full-year results before the February 25 market open
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FOSTER CITY, Calif., July 22, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that it will release its second quarter 2026 financial results and business highlights before the market opens on Wednesday, August 5, 2026, via press release, which will be available on the Investors and Media section of the Company’s website. Geron will host a conference call and webcast at 8:00 a.m. Eastern Time.
A live and archived audio webcast of the conference call will be available from the Investors and Media section of the Company’s website at www.geron.com.
About Geron
Geron is a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer. Our first-in-class telomerase inhibitor RYTELO® (imetelstat) is approved in the United States and the European Union for the treatment of certain adult patients with lower-risk myelodysplastic syndromes with transfusion dependent anemia. We are also conducting a pivotal Phase 3 clinical trial of imetelstat in JAK-inhibitor relapsed/refractory myelofibrosis, as well as studies in other hematologic malignancies. Inhibiting telomerase activity, which is increased in malignant stem and progenitor cells in the bone marrow, aims to potentially reduce proliferation and induce death of malignant cells. To learn more, visit www.geron.com or follow us on LinkedIn.
Investors and Media
Dawn Schottlandt
Senior Vice President, Investor Relations and Corporate Affairs
dschottlandt@geron.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.